I-Mab (IMAB) Stock News

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat and one-on-one meetings on Tuesday, July 29, 2025, at 10:00 AM ET.

The presentation will be available via webcast on I-Mab's website under the News & Events section, remaining accessible for 90 days following the event.

I-Mab (NASDAQ: IMAB) presented positive Phase 1b dose escalation data for givastomig in combination with nivolumab and mFOLFOX6 at ESMO GI 2025. The study evaluated first-line therapy in Claudin 18.2-positive gastric cancer patients.

Key highlights include a confirmed objective response rate (ORR) of 83% (10/12) at selected doses (8 mg/kg and 12 mg/kg) for the ongoing expansion study. The trial demonstrated efficacy across PD-L1 and CLDN18.2 expression levels, with responses in low-expression tumors. With a median follow-up of 9.0 months, the treatment showed favorable tolerability with minimal Grade 3 adverse events.

The study enrolled 17 U.S. patients across three dose levels (5, 8, and 12 mg/kg), achieving a 71% ORR across all doses and a 100% disease control rate. The longest treatment duration was 13.3 months, with 8 patients remaining on treatment at data cutoff.

I-Mab (NASDAQ: IMAB) announced the publication of promising clinical data for givastomig, their bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research. The Phase 1 monotherapy study demonstrated an objective response rate (ORR) of 18% in heavily pretreated Claudin 18.2-positive gastric cancer patients.

Key findings from the 75-patient study include:

• 7 confirmed partial responses in 43 evaluable patients with CLDN18.2-positive advanced gastric cancer
• Disease control rate (DCR) of 49% (21/43 patients)
• Median duration of response of 9.4 months
• Activity observed across Claudin 18.2 expression levels (11% to 100%)
• No dose-limiting toxicity reported up to 15 mg/kg Q2W and 18 mg/kg Q3W

The company will present additional combination therapy data with nivolumab plus mFOLFOX6 at the upcoming ESMO GI Cancers Congress 2025 on July 2nd in Barcelona.

I-Mab (NASDAQ: IMAB) announced positive Phase 1b dose escalation data for givastomig in combination with immunochemotherapy for first-line gastric cancer treatment. The study demonstrated an impressive 71% objective response rate (ORR) across all dose levels, with an even higher 83% ORR in the selected dose expansion cohorts (8 and 12 mg/kg).

Key highlights include rapid and deepening responses even in tumors with low PD-L1 and CLDN18.2 expression, with a 100% disease control rate across all three dose levels. The treatment showed a favorable safety profile with mostly Grade 1 or 2 adverse events. The study enrolled 17 treatment-naïve metastatic gastric cancer patients in the U.S., with 8 patients still continuing treatment, the longest duration being 11.3 months.

I-Mab (NASDAQ: IMAB) announced a virtual investor webinar scheduled for July 8, 2025, at 2:00pm EDT to discuss new data for givastomig, their Claudin 18.2 x 4-1BB bispecific antibody. The webinar will feature Dr. Samuel J. Klempner from Massachusetts General Hospital reviewing Phase 1b combination dose escalation data presented at ESMO GI 2025. The study evaluates givastomig combined with nivolumab and chemotherapy in first-line treatment for Claudin 18.2-positive metastatic gastric cancers, with data from 17 patients. The original data presentation will occur at ESMO GI on July 2, 2025, at 16:50 CEST. The webinar will include a Q&A session, and a replay will be available on I-Mab's website for 90 days.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on June 11, 2025, confirming that its American Depositary Shares (ADSs) had maintained a minimum closing bid price of $1.00 for at least 10 consecutive business days, meeting the requirement under Nasdaq Listing Rule 5550(a)(2). This compliance was achieved on June 10, 2025, and Nasdaq has confirmed that the matter is closed. I-Mab's ADSs will continue to be listed and traded on the Nasdaq stock exchange.

I-Mab (NASDAQ: IMAB), a U.S.-based biotech company specializing in immuno-oncology, has announced its participation in the H.C. Wainwright virtual "HCW@Home" Series on June 17, 2025. The company's management team will engage in a fireside chat focused on Claudin 18.2 as a therapeutic target for gastric cancers, with particular emphasis on their drug candidate givastomig, a Claudin 18.2 x 4-1BB bispecific antibody. The discussion will feature CEO Sean Fu and CMO Phillip Dennis, moderated by H.C. Wainwright Senior Analyst Andres Maldonado. Notably, givastomig's Phase 1 dose escalation study results in combination with immunochemotherapy have been selected for presentation at the upcoming ESMO GI Cancers Congress on July 2, 2025.

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025. The company's management will engage in a fireside chat and one-on-one meetings on June 5 at 3:45 PM ET.

Additionally, I-Mab revealed that new data regarding their lead program, givastomig, has been accepted for a Mini Oral presentation at the ESMO GI Cancers Congress 2025, taking place on July 2, 2025, in Barcelona, Spain.

I-Mab (NASDAQ: IMAB) reported Q1 2025 financial results and business updates. The company's lead program givastomig is progressing well, with new combination data selected for presentation at ESMO GI in July 2025. Financial highlights include $168.6 million in cash and investments as of March 31, 2025, providing runway into 2027. Q1 2025 showed improved financials with net loss of $3.2 million ($0.02 per share), compared to $16.3 million in Q1 2024. R&D expenses decreased to $0.8 million from $6.1 million year-over-year. The company completed patient enrollment ahead of schedule in the first of two Phase 1b dose expansion cohorts for givastomig, with data expected in 1H 2026. I-Mab maintains a strong focus on developing precision immuno-oncology agents for cancer treatment, particularly targeting gastric cancers affecting over 250,000 people globally.